| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | linoleic acid epoxygenase activity | 5.34e-09 | 4 | 23 | 3 | GO:0071614 | |
| GeneOntologyMolecularFunction | retinoic acid 4-hydroxylase activity | 4.82e-07 | 14 | 23 | 3 | GO:0008401 | |
| GeneOntologyMolecularFunction | (R)-limonene 6-monooxygenase activity | 1.27e-06 | 2 | 23 | 2 | GO:0052741 | |
| GeneOntologyMolecularFunction | limonene monooxygenase activity | 1.27e-06 | 2 | 23 | 2 | GO:0019113 | |
| GeneOntologyMolecularFunction | (S)-limonene 6-monooxygenase activity | 1.27e-06 | 2 | 23 | 2 | GO:0018675 | |
| GeneOntologyMolecularFunction | (S)-limonene 7-monooxygenase activity | 1.27e-06 | 2 | 23 | 2 | GO:0018676 | |
| GeneOntologyMolecularFunction | arachidonate epoxygenase activity | 2.66e-06 | 24 | 23 | 3 | GO:0008392 | |
| GeneOntologyMolecularFunction | arachidonate monooxygenase activity | 3.83e-06 | 27 | 23 | 3 | GO:0008391 | |
| GeneOntologyMolecularFunction | arachidonate 11,12-epoxygenase activity | 7.60e-06 | 4 | 23 | 2 | GO:0008405 | |
| GeneOntologyMolecularFunction | aromatase activity | 8.53e-06 | 35 | 23 | 3 | GO:0070330 | |
| GeneOntologyMolecularFunction | fatty acid omega-1 hydroxylase activity | 1.27e-05 | 5 | 23 | 2 | GO:0120502 | |
| GeneOntologyMolecularFunction | long-chain fatty acid omega-1 hydroxylase activity | 1.27e-05 | 5 | 23 | 2 | GO:0120319 | |
| GeneOntologyMolecularFunction | arachidonate 14,15-epoxygenase activity | 1.27e-05 | 5 | 23 | 2 | GO:0008404 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 2.38e-05 | 49 | 23 | 3 | GO:0016712 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor | 3.54e-05 | 8 | 23 | 2 | GO:0033695 | |
| GeneOntologyMolecularFunction | caffeine oxidase activity | 3.54e-05 | 8 | 23 | 2 | GO:0034875 | |
| GeneOntologyMolecularFunction | estrogen 16-alpha-hydroxylase activity | 6.94e-05 | 11 | 23 | 2 | GO:0101020 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on CH or CH2 groups | 1.32e-04 | 15 | 23 | 2 | GO:0016725 | |
| GeneOntologyMolecularFunction | cytoskeletal protein binding | 1.69e-04 | 1099 | 23 | 7 | GO:0008092 | |
| GeneOntologyMolecularFunction | monooxygenase activity | 3.03e-04 | 115 | 23 | 3 | GO:0004497 | |
| GeneOntologyMolecularFunction | cytoskeletal motor activity | 3.27e-04 | 118 | 23 | 3 | GO:0003774 | |
| GeneOntologyMolecularFunction | steroid hydroxylase activity | 6.96e-04 | 34 | 23 | 2 | GO:0008395 | |
| GeneOntologyMolecularFunction | heme binding | 7.11e-04 | 154 | 23 | 3 | GO:0020037 | |
| GeneOntologyMolecularFunction | oxygen binding | 8.25e-04 | 37 | 23 | 2 | GO:0019825 | |
| GeneOntologyMolecularFunction | tetrapyrrole binding | 8.54e-04 | 164 | 23 | 3 | GO:0046906 | |
| GeneOntologyMolecularFunction | microfilament motor activity | 8.70e-04 | 38 | 23 | 2 | GO:0000146 | |
| GeneOntologyMolecularFunction | iron ion binding | 8.84e-04 | 166 | 23 | 3 | GO:0005506 | |
| GeneOntologyMolecularFunction | tubulin binding | 1.33e-03 | 428 | 23 | 4 | GO:0015631 | |
| GeneOntologyMolecularFunction | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 1.39e-03 | 194 | 23 | 3 | GO:0016705 | |
| GeneOntologyMolecularFunction | actin filament binding | 2.17e-03 | 227 | 23 | 3 | GO:0051015 | |
| GeneOntologyMolecularFunction | microtubule binding | 5.12e-03 | 308 | 23 | 3 | GO:0008017 | |
| GeneOntologyMolecularFunction | transition metal ion binding | 1.02e-02 | 1189 | 23 | 5 | GO:0046914 | |
| GeneOntologyMolecularFunction | actin binding | 1.70e-02 | 479 | 23 | 3 | GO:0003779 | |
| GeneOntologyBiologicalProcess | epoxygenase P450 pathway | 1.38e-06 | 22 | 21 | 3 | GO:0019373 | |
| GeneOntologyBiologicalProcess | linoleic acid metabolic process | 1.59e-06 | 23 | 21 | 3 | GO:0043651 | |
| GeneOntologyBiologicalProcess | monoterpenoid metabolic process | 1.48e-05 | 6 | 21 | 2 | GO:0016098 | |
| GeneOntologyBiologicalProcess | supramolecular fiber organization | 2.97e-05 | 957 | 21 | 7 | GO:0097435 | |
| GeneOntologyBiologicalProcess | arachidonate metabolic process | 4.37e-05 | 68 | 21 | 3 | GO:0019369 | |
| GeneOntologyBiologicalProcess | cytoskeleton-dependent intracellular transport | 7.13e-05 | 225 | 21 | 4 | GO:0030705 | |
| GeneOntologyBiologicalProcess | omega-hydroxylase P450 pathway | 8.92e-05 | 14 | 21 | 2 | GO:0097267 | |
| GeneOntologyBiologicalProcess | terpenoid metabolic process | 1.59e-04 | 105 | 21 | 3 | GO:0006721 | |
| GeneOntologyBiologicalProcess | long-chain fatty acid metabolic process | 2.61e-04 | 124 | 21 | 3 | GO:0001676 | |
| GeneOntologyBiologicalProcess | unsaturated fatty acid metabolic process | 2.86e-04 | 128 | 21 | 3 | GO:0033559 | |
| GeneOntologyBiologicalProcess | xenobiotic metabolic process | 3.80e-04 | 141 | 21 | 3 | GO:0006805 | |
| GeneOntologyBiologicalProcess | icosanoid metabolic process | 3.88e-04 | 142 | 21 | 3 | GO:0006690 | |
| GeneOntologyBiologicalProcess | isoprenoid metabolic process | 4.04e-04 | 144 | 21 | 3 | GO:0006720 | |
| GeneOntologyBiologicalProcess | microtubule-based process | 5.01e-04 | 1058 | 21 | 6 | GO:0007017 | |
| GeneOntologyBiologicalProcess | xenobiotic catabolic process | 6.44e-04 | 37 | 21 | 2 | GO:0042178 | |
| GeneOntologyBiologicalProcess | microtubule cytoskeleton organization | 6.53e-04 | 720 | 21 | 5 | GO:0000226 | |
| GeneOntologyBiologicalProcess | olefinic compound metabolic process | 7.74e-04 | 180 | 21 | 3 | GO:0120254 | |
| GeneOntologyBiologicalProcess | intraciliary transport | 1.32e-03 | 53 | 21 | 2 | GO:0042073 | |
| GeneOntologyBiologicalProcess | cellular response to xenobiotic stimulus | 1.42e-03 | 222 | 21 | 3 | GO:0071466 | |
| GeneOntologyBiologicalProcess | actomyosin structure organization | 1.75e-03 | 239 | 21 | 3 | GO:0031032 | |
| GeneOntologyCellularComponent | myosin complex | 2.74e-05 | 59 | 21 | 3 | GO:0016459 | |
| GeneOntologyCellularComponent | myosin filament | 2.84e-04 | 25 | 21 | 2 | GO:0032982 | |
| GeneOntologyCellularComponent | myosin II complex | 3.58e-04 | 28 | 21 | 2 | GO:0016460 | |
| GeneOntologyCellularComponent | centriole | 6.53e-04 | 172 | 21 | 3 | GO:0005814 | |
| GeneOntologyCellularComponent | ciliary basal body | 9.39e-04 | 195 | 21 | 3 | GO:0036064 | |
| Domain | GOLGA6L | 4.42e-11 | 6 | 26 | 4 | IPR026737 | |
| Domain | Golgin_A | 8.91e-09 | 18 | 26 | 4 | IPR024858 | |
| Domain | GOLGA2L5 | 8.91e-09 | 18 | 26 | 4 | PF15070 | |
| Domain | MYOSIN_MOTOR | 1.96e-05 | 38 | 26 | 3 | PS51456 | |
| Domain | Myosin_head | 1.96e-05 | 38 | 26 | 3 | PF00063 | |
| Domain | Myosin_head_motor_dom | 1.96e-05 | 38 | 26 | 3 | IPR001609 | |
| Domain | MYSc | 1.96e-05 | 38 | 26 | 3 | SM00242 | |
| Domain | Liprin | 2.79e-05 | 6 | 26 | 2 | IPR029515 | |
| Domain | Cyt_P450_E_grp-I | 3.27e-05 | 45 | 26 | 3 | IPR002401 | |
| Domain | Cyt_P450_CS | 5.36e-05 | 53 | 26 | 3 | IPR017972 | |
| Domain | CYTOCHROME_P450 | 6.67e-05 | 57 | 26 | 3 | PS00086 | |
| Domain | - | 7.02e-05 | 58 | 26 | 3 | 1.10.630.10 | |
| Domain | p450 | 7.02e-05 | 58 | 26 | 3 | PF00067 | |
| Domain | Cyt_P450 | 7.77e-05 | 60 | 26 | 3 | IPR001128 | |
| Domain | IQ | 1.29e-04 | 71 | 26 | 3 | PF00612 | |
| Domain | IQ | 1.90e-04 | 81 | 26 | 3 | SM00015 | |
| Domain | IQ_motif_EF-hand-BS | 2.60e-04 | 90 | 26 | 3 | IPR000048 | |
| Domain | IQ | 2.86e-04 | 93 | 26 | 3 | PS50096 | |
| Domain | Myosin-like_IQ_dom | 3.14e-04 | 19 | 26 | 2 | IPR027401 | |
| Domain | - | 3.14e-04 | 19 | 26 | 2 | 4.10.270.10 | |
| Domain | SAM_2 | 1.62e-03 | 43 | 26 | 2 | PF07647 | |
| Domain | SAM_1 | 4.01e-03 | 68 | 26 | 2 | PF00536 | |
| Domain | P-loop_NTPase | 5.66e-03 | 848 | 26 | 5 | IPR027417 | |
| Domain | SAM | 6.63e-03 | 88 | 26 | 2 | SM00454 | |
| Domain | SAM_DOMAIN | 7.68e-03 | 95 | 26 | 2 | PS50105 | |
| Domain | SAM | 8.00e-03 | 97 | 26 | 2 | IPR001660 | |
| Domain | - | 9.49e-03 | 106 | 26 | 2 | 1.10.150.50 | |
| Domain | SAM/pointed | 1.15e-02 | 117 | 26 | 2 | IPR013761 | |
| Pathway | WP_EICOSANOID_METABOLISM_VIA_CYTOCHROME_P450_MONOOXYGENASES | 4.33e-07 | 14 | 16 | 3 | MM15842 | |
| Pathway | REACTOME_XENOBIOTICS | 2.10e-06 | 23 | 16 | 3 | M5372 | |
| Pathway | KEGG_LINOLEIC_ACID_METABOLISM | 4.31e-06 | 29 | 16 | 3 | M2920 | |
| Pathway | REACTOME_SYNTHESIS_OF_EPOXY_EET_AND_DIHYDROXYEICOSATRIENOIC_ACIDS_DHET | 3.37e-05 | 8 | 16 | 2 | M27135 | |
| Pathway | KEGG_ARACHIDONIC_ACID_METABOLISM | 3.56e-05 | 58 | 16 | 3 | M5410 | |
| Pathway | REACTOME_SYNTHESIS_OF_16_20_HYDROXYEICOSATETRAENOIC_ACIDS_HETE | 4.33e-05 | 9 | 16 | 2 | M27143 | |
| Pathway | WP_OXIDATION_BY_CYTOCHROME_P450 | 4.36e-05 | 62 | 16 | 3 | M39653 | |
| Pathway | KEGG_RETINOL_METABOLISM | 4.79e-05 | 64 | 16 | 3 | M9488 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 4.79e-05 | 64 | 16 | 3 | M5650 | |
| Pathway | KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 | 6.27e-05 | 70 | 16 | 3 | M16794 | |
| Pathway | REACTOME_CYP2E1_REACTIONS | 6.60e-05 | 11 | 16 | 2 | M27130 | |
| Pathway | KEGG_DRUG_METABOLISM_CYTOCHROME_P450 | 6.82e-05 | 72 | 16 | 3 | M9257 | |
| Pathway | WP_OCTADECANOID_FORMATION_FROM_LINOLEIC_ACID | 7.92e-05 | 12 | 16 | 2 | M48064 | |
| Pathway | REACTOME_ACETYLCHOLINE_NEUROTRANSMITTER_RELEASE_CYCLE | 1.63e-04 | 17 | 16 | 2 | M93 | |
| Pathway | REACTOME_ACETYLCHOLINE_NEUROTRANSMITTER_RELEASE_CYCLE | 1.63e-04 | 17 | 16 | 2 | MM14907 | |
| Pathway | REACTOME_SEROTONIN_NEUROTRANSMITTER_RELEASE_CYCLE | 1.83e-04 | 18 | 16 | 2 | M27043 | |
| Pathway | REACTOME_NOREPINEPHRINE_NEUROTRANSMITTER_RELEASE_CYCLE | 1.83e-04 | 18 | 16 | 2 | M13015 | |
| Pathway | REACTOME_SEROTONIN_NEUROTRANSMITTER_RELEASE_CYCLE | 1.83e-04 | 18 | 16 | 2 | MM14702 | |
| Pathway | REACTOME_NOREPINEPHRINE_NEUROTRANSMITTER_RELEASE_CYCLE | 1.83e-04 | 18 | 16 | 2 | MM14703 | |
| Pathway | REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS | 2.04e-04 | 104 | 16 | 3 | M738 | |
| Pathway | REACTOME_RECEPTOR_TYPE_TYROSINE_PROTEIN_PHOSPHATASES | 2.27e-04 | 20 | 16 | 2 | M27290 | |
| Pathway | REACTOME_RECEPTOR_TYPE_TYROSINE_PROTEIN_PHOSPHATASES | 2.27e-04 | 20 | 16 | 2 | MM14991 | |
| Pathway | WP_TAMOXIFEN_METABOLISM | 2.50e-04 | 21 | 16 | 2 | M39631 | |
| Pathway | REACTOME_DOPAMINE_NEUROTRANSMITTER_RELEASE_CYCLE | 3.01e-04 | 23 | 16 | 2 | MM14852 | |
| Pathway | REACTOME_DOPAMINE_NEUROTRANSMITTER_RELEASE_CYCLE | 3.01e-04 | 23 | 16 | 2 | M12627 | |
| Pathway | WP_ESTROGEN_METABOLISM_WP5276 | 3.29e-04 | 24 | 16 | 2 | M46445 | |
| Pathway | REACTOME_GLUTAMATE_NEUROTRANSMITTER_RELEASE_CYCLE | 3.29e-04 | 24 | 16 | 2 | M630 | |
| Pathway | REACTOME_GLUTAMATE_NEUROTRANSMITTER_RELEASE_CYCLE | 3.29e-04 | 24 | 16 | 2 | MM14834 | |
| Pathway | REACTOME_XENOBIOTICS | 3.57e-04 | 25 | 16 | 2 | MM14846 | |
| Pathway | WP_CANNABINOID_RECEPTOR_SIGNALING | 4.82e-04 | 29 | 16 | 2 | M39676 | |
| Pathway | WP_CONSTITUTIVE_ANDROSTANE_RECEPTOR_PATHWAY | 5.51e-04 | 31 | 16 | 2 | M39476 | |
| Pathway | WP_PREGNANE_X_RECEPTOR_PATHWAY | 5.87e-04 | 32 | 16 | 2 | M39567 | |
| Pathway | WP_METAPATHWAY_BIOTRANSFORMATION_PHASE_I_AND_II | 1.06e-03 | 183 | 16 | 3 | M39588 | |
| Pathway | REACTOME_ASPIRIN_ADME | 1.11e-03 | 44 | 16 | 2 | M45014 | |
| Pathway | REACTOME_CILIUM_ASSEMBLY | 1.39e-03 | 201 | 16 | 3 | M27472 | |
| Pathway | REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE | 1.49e-03 | 51 | 16 | 2 | MM14499 | |
| Pathway | REACTOME_NEUROTRANSMITTER_RELEASE_CYCLE | 1.49e-03 | 51 | 16 | 2 | M4281 | |
| Pathway | REACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE | 1.74e-03 | 217 | 16 | 3 | MM14708 | |
| Pathway | REACTOME_BIOLOGICAL_OXIDATIONS | 1.81e-03 | 220 | 16 | 3 | M10320 | |
| Pathway | REACTOME_ARACHIDONIC_ACID_METABOLISM | 1.99e-03 | 59 | 16 | 2 | M27140 | |
| Pathway | REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE | 2.48e-03 | 66 | 16 | 2 | MM14839 | |
| Pathway | REACTOME_PROTEIN_PROTEIN_INTERACTIONS_AT_SYNAPSES | 2.56e-03 | 67 | 16 | 2 | MM15327 | |
| Pathway | REACTOME_AURKA_ACTIVATION_BY_TPX2 | 2.87e-03 | 71 | 16 | 2 | MM15495 | |
| Pathway | REACTOME_AURKA_ACTIVATION_BY_TPX2 | 2.95e-03 | 72 | 16 | 2 | M27749 | |
| Pathway | REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES | 3.71e-03 | 81 | 16 | 2 | M748 | |
| Pathway | REACTOME_REGULATION_OF_PLK1_ACTIVITY_AT_G2_M_TRANSITION | 4.08e-03 | 85 | 16 | 2 | MM14906 | |
| Pathway | REACTOME_ORGANELLE_BIOGENESIS_AND_MAINTENANCE | 4.23e-03 | 297 | 16 | 3 | M27050 | |
| Pathway | REACTOME_PROTEIN_PROTEIN_INTERACTIONS_AT_SYNAPSES | 4.27e-03 | 87 | 16 | 2 | M27617 | |
| Pathway | REACTOME_REGULATION_OF_PLK1_ACTIVITY_AT_G2_M_TRANSITION | 4.27e-03 | 87 | 16 | 2 | M27194 | |
| Pathway | REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES | 4.56e-03 | 90 | 16 | 2 | MM14979 | |
| Pathway | REACTOME_RECRUITMENT_OF_NUMA_TO_MITOTIC_CENTROSOMES | 5.07e-03 | 95 | 16 | 2 | M6729 | |
| Pathway | REACTOME_ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE | 5.18e-03 | 96 | 16 | 2 | MM15207 | |
| Pathway | REACTOME_ANCHORING_OF_THE_BASAL_BODY_TO_THE_PLASMA_MEMBRANE | 5.28e-03 | 97 | 16 | 2 | M27478 | |
| Pathway | REACTOME_PHASE_I_FUNCTIONALIZATION_OF_COMPOUNDS | 6.16e-03 | 105 | 16 | 2 | MM14842 | |
| Pathway | REACTOME_DRUG_ADME | 6.62e-03 | 109 | 16 | 2 | M45012 | |
| Pathway | REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS | 7.22e-03 | 114 | 16 | 2 | MM14814 | |
| Pathway | REACTOME_PARASITE_INFECTION | 7.47e-03 | 116 | 16 | 2 | M29843 | |
| Pathway | REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS | 1.12e-02 | 143 | 16 | 2 | M27107 | |
| Pathway | REACTOME_FATTY_ACID_METABOLISM | 1.66e-02 | 176 | 16 | 2 | M27854 | |
| Pathway | REACTOME_MITOTIC_G2_G2_M_PHASES | 1.80e-02 | 184 | 16 | 2 | MM15145 | |
| Pathway | REACTOME_MITOTIC_G2_G2_M_PHASES | 2.11e-02 | 200 | 16 | 2 | M864 | |
| Pathway | REACTOME_MITOTIC_PROMETAPHASE | 2.15e-02 | 202 | 16 | 2 | MM15362 | |
| Pathway | REACTOME_MITOTIC_PROMETAPHASE | 2.19e-02 | 204 | 16 | 2 | M4217 | |
| Pubmed | 3.71e-10 | 3 | 26 | 3 | 15102943 | ||
| Pubmed | 3.71e-10 | 3 | 26 | 3 | 8095407 | ||
| Pubmed | 1.48e-09 | 4 | 26 | 3 | 2009263 | ||
| Pubmed | 1.48e-09 | 4 | 26 | 3 | 21798861 | ||
| Pubmed | 1.48e-09 | 4 | 26 | 3 | 23755828 | ||
| Pubmed | 1.48e-09 | 4 | 26 | 3 | 19706858 | ||
| Pubmed | Biochemistry and molecular biology of the human CYP2C subfamily. | 1.48e-09 | 4 | 26 | 3 | 7704034 | |
| Pubmed | A genome-wide association study of acenocoumarol maintenance dosage. | 7.41e-09 | 6 | 26 | 3 | 19578179 | |
| Pubmed | Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population. | 1.34e-07 | 14 | 26 | 3 | 19290787 | |
| Pubmed | Association of warfarin dose with genes involved in its action and metabolism. | 2.06e-07 | 16 | 26 | 3 | 17048007 | |
| Pubmed | Molecular genetics of the human cytochrome P450 monooxygenase superfamily. | 4.19e-07 | 20 | 26 | 3 | 9890157 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 17504998 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 16198656 | ||
| Pubmed | Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors. | 5.37e-07 | 2 | 26 | 2 | 24519941 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 14623888 | ||
| Pubmed | Cytochrome P450 polymorphisms in patients with Behcet's disease. | 5.37e-07 | 2 | 26 | 2 | 17269966 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 11950794 | ||
| Pubmed | [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration]. | 5.37e-07 | 2 | 26 | 2 | 15569425 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 17279092 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 22589111 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 32216088 | ||
| Pubmed | cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenase. | 5.37e-07 | 2 | 26 | 2 | 8130255 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19534586 | ||
| Pubmed | CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. | 5.37e-07 | 2 | 26 | 2 | 15660966 | |
| Pubmed | Important amino acid residues that confer CYP2C19 selective activity to CYP2C9. | 5.37e-07 | 2 | 26 | 2 | 18511451 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 18154472 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 27353638 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 17298483 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 33115391 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 17562299 | ||
| Pubmed | Developmental expression of human hepatic CYP2C9 and CYP2C19. | 5.37e-07 | 2 | 26 | 2 | 14634042 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 22918969 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 36960518 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 26690534 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 33232775 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 32567426 | ||
| Pubmed | CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract. | 5.37e-07 | 2 | 26 | 2 | 10908295 | |
| Pubmed | Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. | 5.37e-07 | 2 | 26 | 2 | 17868191 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 32868386 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 27617498 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19199010 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 1847130 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 16873909 | ||
| Pubmed | Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes. | 5.37e-07 | 2 | 26 | 2 | 17599801 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19038035 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 17304159 | ||
| Pubmed | Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. | 5.37e-07 | 2 | 26 | 2 | 8110777 | |
| Pubmed | Genetic Polymorphisms of CYP2C9/CYP2C19 in Chronic Obstructive Pulmonary Disease. | 5.37e-07 | 2 | 26 | 2 | 32757668 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 106274 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19358898 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 15385837 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 25518510 | ||
| Pubmed | Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. | 5.37e-07 | 2 | 26 | 2 | 8333835 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 20390258 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19761366 | ||
| Pubmed | Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. | 5.37e-07 | 2 | 26 | 2 | 14616425 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 15776277 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 34438105 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 15842554 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 24492587 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 12496751 | ||
| Pubmed | Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. | 5.37e-07 | 2 | 26 | 2 | 24403552 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19136640 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 2895926 | ||
| Pubmed | A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram. | 5.37e-07 | 2 | 26 | 2 | 33759177 | |
| Pubmed | Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage. | 5.37e-07 | 2 | 26 | 2 | 35748067 | |
| Pubmed | Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. | 5.37e-07 | 2 | 26 | 2 | 16232205 | |
| Pubmed | Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development. | 5.37e-07 | 2 | 26 | 2 | 32587777 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 20845310 | ||
| Pubmed | Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. | 5.37e-07 | 2 | 26 | 2 | 17201743 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 32683556 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 20831536 | ||
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 15855721 | ||
| Pubmed | Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. | 5.37e-07 | 2 | 26 | 2 | 9721182 | |
| Pubmed | 5.37e-07 | 2 | 26 | 2 | 19847408 | ||
| Pubmed | 1.49e-06 | 30 | 26 | 3 | 20529763 | ||
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 28687336 | ||
| Pubmed | Distribution of CYP2C polymorphisms in an Amerindian population of Brazil. | 1.61e-06 | 3 | 26 | 2 | 21977947 | |
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 16220110 | ||
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 31128914 | ||
| Pubmed | Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology. | 1.61e-06 | 3 | 26 | 2 | 15090156 | |
| Pubmed | Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. | 1.61e-06 | 3 | 26 | 2 | 29181698 | |
| Pubmed | Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus? | 1.61e-06 | 3 | 26 | 2 | 19192051 | |
| Pubmed | Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response. | 1.61e-06 | 3 | 26 | 2 | 24222221 | |
| Pubmed | Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. | 1.61e-06 | 3 | 26 | 2 | 20885015 | |
| Pubmed | Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. | 1.61e-06 | 3 | 26 | 2 | 19151603 | |
| Pubmed | Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. | 1.61e-06 | 3 | 26 | 2 | 23941071 | |
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 20665013 | ||
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 22708815 | ||
| Pubmed | Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. | 1.61e-06 | 3 | 26 | 2 | 17827141 | |
| Pubmed | CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. | 1.61e-06 | 3 | 26 | 2 | 19617466 | |
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 27803446 | ||
| Pubmed | Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series. | 1.61e-06 | 3 | 26 | 2 | 25803758 | |
| Pubmed | Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. | 1.61e-06 | 3 | 26 | 2 | 15177309 | |
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 21766908 | ||
| Pubmed | Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. | 1.61e-06 | 3 | 26 | 2 | 12950145 | |
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 32469422 | ||
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 20637959 | ||
| Pubmed | 1.61e-06 | 3 | 26 | 2 | 23081704 | ||
| Pubmed | The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. | 1.61e-06 | 3 | 26 | 2 | 10704292 | |
| Interaction | WHAMMP3 interactions | 4.61e-09 | 119 | 24 | 6 | int:WHAMMP3 | |
| Interaction | CYP2C19 interactions | 1.48e-08 | 5 | 24 | 3 | int:CYP2C19 | |
| Interaction | CYP2C18 interactions | 4.26e-06 | 27 | 24 | 3 | int:CYP2C18 | |
| Interaction | CYP2C9 interactions | 6.82e-06 | 105 | 24 | 4 | int:CYP2C9 | |
| Interaction | CDK18 interactions | 1.64e-05 | 131 | 24 | 4 | int:CDK18 | |
| Interaction | ZFP1 interactions | 2.04e-05 | 45 | 24 | 3 | int:ZFP1 | |
| Interaction | CEP95 interactions | 2.80e-05 | 50 | 24 | 3 | int:CEP95 | |
| Interaction | HBZ interactions | 3.54e-05 | 54 | 24 | 3 | int:HBZ | |
| Interaction | ZNF80 interactions | 7.43e-05 | 11 | 24 | 2 | int:ZNF80 | |
| Interaction | CCDC187 interactions | 9.85e-05 | 76 | 24 | 3 | int:CCDC187 | |
| Interaction | TPGS1 interactions | 1.19e-04 | 81 | 24 | 3 | int:TPGS1 | |
| Interaction | ZNF844 interactions | 1.23e-04 | 14 | 24 | 2 | int:ZNF844 | |
| Interaction | ZNF32 interactions | 1.61e-04 | 16 | 24 | 2 | int:ZNF32 | |
| Interaction | MED4 interactions | 1.62e-04 | 450 | 24 | 5 | int:MED4 | |
| Interaction | FAM167A interactions | 1.97e-04 | 96 | 24 | 3 | int:FAM167A | |
| Interaction | RCOR1 interactions | 2.51e-04 | 494 | 24 | 5 | int:RCOR1 | |
| Interaction | CEP250 interactions | 3.42e-04 | 287 | 24 | 4 | int:CEP250 | |
| Interaction | TBC1D30 interactions | 3.69e-04 | 24 | 24 | 2 | int:TBC1D30 | |
| Interaction | LENG1 interactions | 3.71e-04 | 119 | 24 | 3 | int:LENG1 | |
| Interaction | MIB1 interactions | 3.79e-04 | 295 | 24 | 4 | int:MIB1 | |
| Interaction | PRPF18 interactions | 3.80e-04 | 120 | 24 | 3 | int:PRPF18 | |
| Interaction | BRK1 interactions | 4.19e-04 | 124 | 24 | 3 | int:BRK1 | |
| Interaction | LCA5 interactions | 4.29e-04 | 125 | 24 | 3 | int:LCA5 | |
| Interaction | ZNF250 interactions | 4.39e-04 | 126 | 24 | 3 | int:ZNF250 | |
| Interaction | IL16 interactions | 4.49e-04 | 127 | 24 | 3 | int:IL16 | |
| Interaction | SYCE1 interactions | 4.49e-04 | 127 | 24 | 3 | int:SYCE1 | |
| Interaction | ZNF587 interactions | 5.37e-04 | 135 | 24 | 3 | int:ZNF587 | |
| Interaction | KRT23 interactions | 6.19e-04 | 31 | 24 | 2 | int:KRT23 | |
| Interaction | ZNF329 interactions | 6.60e-04 | 32 | 24 | 2 | int:ZNF329 | |
| Interaction | TCEANC interactions | 6.61e-04 | 145 | 24 | 3 | int:TCEANC | |
| Interaction | KDM1A interactions | 6.65e-04 | 941 | 24 | 6 | int:KDM1A | |
| Interaction | PHF21A interactions | 6.69e-04 | 343 | 24 | 4 | int:PHF21A | |
| Interaction | TULP3 interactions | 6.91e-04 | 346 | 24 | 4 | int:TULP3 | |
| Interaction | BCL6B interactions | 7.02e-04 | 33 | 24 | 2 | int:BCL6B | |
| Interaction | FLYWCH1 interactions | 7.02e-04 | 33 | 24 | 2 | int:FLYWCH1 | |
| Interaction | LNX1 interactions | 7.84e-04 | 634 | 24 | 5 | int:LNX1 | |
| Interaction | PTP4A3 interactions | 7.87e-04 | 154 | 24 | 3 | int:PTP4A3 | |
| Interaction | NIN interactions | 7.94e-04 | 359 | 24 | 4 | int:NIN | |
| Interaction | BTNL9 interactions | 8.17e-04 | 156 | 24 | 3 | int:BTNL9 | |
| Interaction | FAM161A interactions | 8.17e-04 | 156 | 24 | 3 | int:FAM161A | |
| Interaction | ODF2 interactions | 8.48e-04 | 158 | 24 | 3 | int:ODF2 | |
| Interaction | CCDC116 interactions | 8.82e-04 | 37 | 24 | 2 | int:CCDC116 | |
| Interaction | PPFIA2 interactions | 8.82e-04 | 37 | 24 | 2 | int:PPFIA2 | |
| Cytoband | 10q24 | 9.23e-07 | 35 | 25 | 3 | 10q24 | |
| Cytoband | 15q25.2 | 1.74e-06 | 43 | 25 | 3 | 15q25.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr15q25 | 9.03e-05 | 160 | 25 | 3 | chr15q25 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr10q23 | 1.62e-04 | 195 | 25 | 3 | chr10q23 | |
| Cytoband | 22q13.1 | 9.89e-04 | 85 | 25 | 2 | 22q13.1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr22q12 | 7.24e-03 | 235 | 25 | 2 | chr22q12 | |
| GeneFamily | Cytochrome P450 family 2 | 3.66e-06 | 35 | 16 | 3 | 1001 | |
| GeneFamily | Sterile alpha motif domain containing | 2.69e-03 | 88 | 16 | 2 | 760 | |
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 1.40e-02 | 206 | 16 | 2 | 682 | |
| Coexpression | WENG_POR_DOSAGE | 2.69e-06 | 30 | 24 | 3 | MM1199 | |
| Coexpression | BUSSLINGER_DUODENAL_MATURE_ENTEROCYTES | 3.30e-06 | 259 | 24 | 5 | M40029 | |
| Coexpression | WIEMANN_TELOMERE_SHORTENING_AND_CHRONIC_LIVER_DAMAGE_DN | 1.20e-05 | 6 | 24 | 2 | MM971 | |
| Coexpression | BROWNE_HCMV_INFECTION_16HR_UP | 4.74e-05 | 223 | 24 | 4 | M11383 | |
| Coexpression | DESCARTES_MAIN_FETAL_MUC13_DMBT1_POSITIVE_CELLS | 1.40e-04 | 111 | 24 | 3 | M40139 | |
| Coexpression | SAENZ_DETOX_PATHWAY_AND_CARCINOGENESIS_DN | 1.51e-04 | 20 | 24 | 2 | MM1104 | |
| Coexpression | WENG_POR_DOSAGE | 2.01e-04 | 23 | 24 | 2 | M1634 | |
| Coexpression | TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_DN | 2.19e-04 | 24 | 24 | 2 | MM708 | |
| Coexpression | WENG_POR_TARGETS_GLOBAL_DN | 2.78e-04 | 27 | 24 | 2 | MM1192 | |
| ToppCell | RV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper | 4.19e-06 | 189 | 26 | 4 | 0a82931b5f6c0a6427ca3edd5e2235ac49099d40 | |
| ToppCell | TCGA-Thymus-Primary_Tumor-Thymoma-Type_B3-5|TCGA-Thymus / Sample_Type by Project: Shred V9 | 4.60e-05 | 120 | 26 | 3 | 9d4e630e1d3b9adf94a1884071bfe46edaa3f0c1 | |
| ToppCell | LA-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper | 7.12e-05 | 139 | 26 | 3 | 9e2a84d5ed7232b70eadbba754d9ca13f2d50fe9 | |
| ToppCell | TCGA-Bile_Duct|World / Sample_Type by Project: Shred V9 | 7.28e-05 | 140 | 26 | 3 | ca8a0ccbc2f501b759864fe9bb06dc8b44b6b31f | |
| ToppCell | LA-15._Ventricular_Cardiomyocyte_III|LA / Chamber and Cluster_Paper | 8.41e-05 | 147 | 26 | 3 | 8970eb6b82589f39439c61a57d999661ec8342de | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-Degenerative_Endothelial_Cell-Degenerative_endothelial_cell_-_unspecif|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.38e-04 | 174 | 26 | 3 | 4d8c4a7d8f4972da68cebe0a79eb1a14ec546121 | |
| ToppCell | COVID-19-Heart-CM_3|Heart / Disease (COVID-19 only), tissue and cell type | 1.58e-04 | 182 | 26 | 3 | 287fcc3897ae08841f6f85ae6c9cef16f75b1dd1 | |
| ToppCell | 3'-Adult-SmallIntestine-Epithelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.63e-04 | 184 | 26 | 3 | ed7a8e79e5723a5f5a03f542203d9e50bdef5f50 | |
| ToppCell | 3'-Adult-SmallIntestine-Epithelial-mature_enterocytic|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.69e-04 | 186 | 26 | 3 | bdd9d3a432aab46e733469b362f0064d35c1ac49 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Lymphocytic-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.69e-04 | 186 | 26 | 3 | f5468e03321ea2083e223eb0d92c3a9307039569 | |
| ToppCell | 3'-Adult-SmallIntestine-Epithelial-mature_enterocytic-Enterocyte|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.71e-04 | 187 | 26 | 3 | 9042bd0f57213a51503d9df2e4dce3209b7772d3 | |
| ToppCell | RV-15._Ventricular_Cardiomyocyte_III|RV / Chamber and Cluster_Paper | 1.79e-04 | 190 | 26 | 3 | 93c3188dfeb0b2f9889f8ae9b9c1f2f34129c99b | |
| Computational | Cytochrome P450. | 9.75e-07 | 14 | 16 | 3 | MODULE_106 | |
| Computational | Neighborhood of CASP2 | 4.37e-04 | 103 | 16 | 3 | MORF_CASP2 | |
| Computational | Genes in the cancer module 135. | 6.11e-04 | 25 | 16 | 2 | MODULE_135 | |
| Drug | 4',5-dihydroxydiclofenac | 2.05e-08 | 6 | 24 | 3 | CID003052567 | |
| Drug | 3'-hydroxydiclofenac | 2.05e-08 | 6 | 24 | 3 | CID000112230 | |
| Drug | Acenocoumarol | 8.61e-08 | 9 | 24 | 3 | ctd:D000074 | |
| Drug | 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide | 8.61e-08 | 9 | 24 | 3 | ctd:C545880 | |
| Drug | 5-hydroxydiclofenac | 2.25e-07 | 12 | 24 | 3 | CID003052566 | |
| Drug | 2'-(glutathion-S-yl)-deschlorodiclofenac | 4.64e-07 | 15 | 24 | 3 | ctd:C586542 | |
| Drug | 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane | 5.71e-07 | 16 | 24 | 3 | ctd:C495657 | |
| Drug | Azamulinum | 8.31e-07 | 18 | 24 | 3 | CID003086060 | |
| Drug | D 703 | 8.31e-07 | 18 | 24 | 3 | CID000054088 | |
| Drug | hydroxytolbutamide | 9.86e-07 | 19 | 24 | 3 | CID000003656 | |
| Drug | dibenzylfluorescein | 1.06e-06 | 2 | 24 | 2 | ctd:C558664 | |
| Drug | 3C etc | 1.16e-06 | 20 | 24 | 3 | CID000164045 | |
| Drug | Tolbutamide | 2.33e-06 | 25 | 24 | 3 | ctd:D014044 | |
| Drug | 1,4-naphthoquinone | 2.63e-06 | 26 | 24 | 3 | ctd:C035342 | |
| Drug | picoxystrobin | 3.19e-06 | 3 | 24 | 2 | ctd:C556557 | |
| Drug | 2-hydroxychlorpropamide | 3.19e-06 | 3 | 24 | 2 | CID003082454 | |
| Drug | mono-N-demethyladinazolam | 3.19e-06 | 3 | 24 | 2 | ctd:C050132 | |
| Drug | Delavirdine | 3.19e-06 | 3 | 24 | 2 | ctd:D020008 | |
| Drug | (hydrochloride) | 3.69e-06 | 29 | 24 | 3 | CID000004923 | |
| Drug | tofisopam | 3.69e-06 | 29 | 24 | 3 | CID000005502 | |
| Drug | triphenylstannanylium | 3.69e-06 | 29 | 24 | 3 | CID000091481 | |
| Drug | BP-7,8-oxide | 5.00e-06 | 32 | 24 | 3 | CID000037455 | |
| Drug | 1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea | 6.38e-06 | 4 | 24 | 2 | ctd:C558737 | |
| Drug | 7,8-dihydromethysticin | 6.38e-06 | 4 | 24 | 2 | ctd:C107882 | |
| Drug | rabeprazole-thioether | 6.38e-06 | 4 | 24 | 2 | ctd:C523099 | |
| Drug | methysticin | 6.38e-06 | 4 | 24 | 2 | ctd:C076881 | |
| Drug | benfuracarb | 1.06e-05 | 5 | 24 | 2 | ctd:C096128 | |
| Drug | bufuralol | 1.06e-05 | 5 | 24 | 2 | ctd:C010831 | |
| Drug | 2-oxo-clopidogrel | 1.06e-05 | 5 | 24 | 2 | ctd:C540904 | |
| Drug | mono(2-ethyl-5-hydroxyhexyl) phthalate | 1.06e-05 | 5 | 24 | 2 | ctd:C479069 | |
| Drug | furafylline | 1.07e-05 | 41 | 24 | 3 | CID000003433 | |
| Drug | sulfaphenazole | 1.32e-05 | 44 | 24 | 3 | CID000005335 | |
| Drug | polybrominated biphenyl | 1.32e-05 | 44 | 24 | 3 | CID000042948 | |
| Drug | mono(2-ethyl-5-oxohexyl)phthalate | 1.59e-05 | 6 | 24 | 2 | ctd:C080276 | |
| Drug | 4'-hydroxyflurbiprofen | 1.59e-05 | 6 | 24 | 2 | CID000157678 | |
| Drug | AC1O5Z5L | 1.59e-05 | 6 | 24 | 2 | CID006443527 | |
| Drug | mepirodipine | 1.59e-05 | 6 | 24 | 2 | ctd:C050699 | |
| Drug | 4,4'-cyclohexylidenebisphenol | 1.59e-05 | 6 | 24 | 2 | ctd:C570106 | |
| Drug | mono-OH | 1.59e-05 | 6 | 24 | 2 | CID000183679 | |
| Drug | Cyclodextrins | 1.59e-05 | 6 | 24 | 2 | ctd:D003505 | |
| Drug | avasimibe | 1.59e-05 | 6 | 24 | 2 | ctd:C423185 | |
| Drug | 19-HETE | 1.84e-05 | 49 | 24 | 3 | CID006439528 | |
| Drug | 6-hydroxymelatonin | 1.95e-05 | 50 | 24 | 3 | CID000001864 | |
| Drug | formycin triphosphate | 2.07e-05 | 51 | 24 | 3 | CID000122274 | |
| Drug | sulprofos | 2.23e-05 | 7 | 24 | 2 | CID000037125 | |
| Drug | quinidine-N-oxide | 2.23e-05 | 7 | 24 | 2 | CID000050979 | |
| Drug | 5-n-butyl-pyrazolo(1,5-a)pyrimidine | 2.23e-05 | 7 | 24 | 2 | ctd:C547858 | |
| Drug | 5-fluorotryptamine | 2.23e-05 | 7 | 24 | 2 | ctd:C034536 | |
| Drug | 12-hydroxyellipticine | 2.23e-05 | 7 | 24 | 2 | ctd:C517214 | |
| Drug | 6-Fluoro-6-desoxyoxymorphone | 2.23e-05 | 7 | 24 | 2 | CID005486899 | |
| Drug | 16-O-demethylaconitine | 2.23e-05 | 7 | 24 | 2 | ctd:C486136 | |
| Drug | Voriconazole | 2.23e-05 | 7 | 24 | 2 | ctd:D065819 | |
| Drug | 5-hydroxydiclofenac | 2.23e-05 | 7 | 24 | 2 | ctd:C117715 | |
| Drug | desmethyltrimipramine | 2.23e-05 | 7 | 24 | 2 | CID000160632 | |
| Drug | triazolam | 2.46e-05 | 54 | 24 | 3 | CID000005556 | |
| Drug | sulforidazine | 2.97e-05 | 8 | 24 | 2 | CID000031765 | |
| Drug | clobazam | 2.97e-05 | 8 | 24 | 2 | ctd:C012255 | |
| Drug | 13-hydroxyeicosatetraenoic acid | 2.97e-05 | 8 | 24 | 2 | CID006439499 | |
| Drug | desmethylmaprotiline | 2.97e-05 | 8 | 24 | 2 | CID000119409 | |
| Drug | 5-fluoro-alpha-methyltryptamine | 2.97e-05 | 8 | 24 | 2 | ctd:C051101 | |
| Drug | germacrone | 2.97e-05 | 8 | 24 | 2 | ctd:C048393 | |
| Drug | 5-methyltryptamine | 2.97e-05 | 8 | 24 | 2 | ctd:C027552 | |
| Drug | 11 beta-hydroxytestosterone | 2.97e-05 | 8 | 24 | 2 | CID000114920 | |
| Drug | 7-methyltryptamine | 2.97e-05 | 8 | 24 | 2 | ctd:C036696 | |
| Drug | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | 2.97e-05 | 8 | 24 | 2 | ctd:C585955 | |
| Drug | AC1L4AGK | 2.97e-05 | 8 | 24 | 2 | CID000182186 | |
| Drug | 11-HODE | 2.97e-05 | 8 | 24 | 2 | CID006438497 | |
| Drug | 5-bromotryptamine | 2.97e-05 | 8 | 24 | 2 | ctd:C040997 | |
| Drug | 4-hydroxyalprazolam | 2.97e-05 | 8 | 24 | 2 | CID000182017 | |
| Drug | purealin | 3.06e-05 | 58 | 24 | 3 | CID006419303 | |
| Drug | miconazole | 3.22e-05 | 59 | 24 | 3 | CID000004189 | |
| Drug | Lansoprazole | 3.56e-05 | 61 | 24 | 3 | ctd:D064747 | |
| Drug | BP-4,5-oxide | 3.56e-05 | 61 | 24 | 3 | CID000037786 | |
| Drug | 5-chlorotryptamine | 3.82e-05 | 9 | 24 | 2 | ctd:C529169 | |
| Drug | 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate | 3.82e-05 | 9 | 24 | 2 | ctd:C109602 | |
| Drug | 2-nitroanisole | 3.82e-05 | 9 | 24 | 2 | ctd:C005328 | |
| Drug | 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid | 3.82e-05 | 9 | 24 | 2 | ctd:C000588958 | |
| Drug | Tryptamines | 3.82e-05 | 9 | 24 | 2 | ctd:D014363 | |
| Drug | N-desmethylclobazam | 3.82e-05 | 9 | 24 | 2 | CID000089657 | |
| Drug | phenylcyclopropane | 3.82e-05 | 9 | 24 | 2 | CID000070112 | |
| Drug | cis-linoleic acid | 3.82e-05 | 9 | 24 | 2 | CID006431005 | |
| Drug | Fluorescein | 3.82e-05 | 9 | 24 | 2 | ctd:D019793 | |
| Drug | AC1L8U1Y | 3.82e-05 | 9 | 24 | 2 | CID000408120 | |
| Drug | chlorzoxazone | 3.92e-05 | 63 | 24 | 3 | CID000002733 | |
| Drug | diazepam | 4.29e-05 | 189 | 24 | 4 | CID000003016 | |
| Drug | propoxyphene | 4.72e-05 | 67 | 24 | 3 | CID000010100 | |
| Drug | piperonyl butoxide | 4.72e-05 | 67 | 24 | 3 | CID000005794 | |
| Drug | Mephenytoin | 4.77e-05 | 10 | 24 | 2 | ctd:D008617 | |
| Drug | sulconazole | 4.77e-05 | 10 | 24 | 2 | CID000005318 | |
| Drug | 13-hydroxyellipticine | 4.77e-05 | 10 | 24 | 2 | ctd:C517215 | |
| Drug | 3-hydroxyflunitrazepam | 4.77e-05 | 10 | 24 | 2 | CID000128908 | |
| Drug | AHMA | 4.77e-05 | 10 | 24 | 2 | CID000216240 | |
| Drug | S)-3-phenylpiperidine | 4.77e-05 | 10 | 24 | 2 | CID000101021 | |
| Drug | Celsior | 4.77e-05 | 10 | 24 | 2 | ctd:C088453 | |
| Drug | 8-hydroxydaidzein | 4.77e-05 | 10 | 24 | 2 | CID005466139 | |
| Drug | Melarsoprol | 4.77e-05 | 10 | 24 | 2 | ctd:D008549 | |
| Drug | sitaxsentan | 4.77e-05 | 10 | 24 | 2 | ctd:C106276 | |
| Drug | norketobemidone | 4.77e-05 | 10 | 24 | 2 | CID000161154 | |
| Drug | 5,6-epoxyeicosatrienoic acid | 4.93e-05 | 68 | 24 | 3 | CID000001778 | |
| Drug | raloxifene hydrochloride; Down 200; 0.1uM; MCF7; HG-U133A | 5.14e-05 | 198 | 24 | 4 | 202_DN | |
| Disease | X-21258 measurement | 4.14e-10 | 3 | 23 | 3 | EFO_0800802 | |
| Disease | X-14473 measurement | 5.81e-07 | 2 | 23 | 2 | EFO_0021370 | |
| Disease | cyclo(leu-pro) measurement | 1.74e-06 | 3 | 23 | 2 | EFO_0800676 | |
| Disease | glycine conjugate of C10H14O2 (1) measurement | 1.22e-05 | 7 | 23 | 2 | EFO_0800655 | |
| Disease | plasma clozapine-to-N-desmethylclozapine ratio measurement | 2.09e-05 | 9 | 23 | 2 | EFO_0600040 | |
| Disease | X-11308 measurement | 3.18e-05 | 11 | 23 | 2 | EFO_0800693 | |
| Disease | thymol sulfate measurement | 3.82e-05 | 12 | 23 | 2 | EFO_0021170 | |
| Disease | S-6-hydroxywarfarin to S-warfarin ratio measurement | 4.35e-05 | 88 | 23 | 3 | EFO_0803332 | |
| Disease | S-warfarin to R-warfarin ratio measurement | 5.46e-05 | 95 | 23 | 3 | EFO_0803331 | |
| Disease | metabolonic lactone sulfate measurement | 9.86e-05 | 19 | 23 | 2 | EFO_0800659 | |
| Disease | platelet reactivity measurement, response to clopidogrel | 1.46e-04 | 23 | 23 | 2 | EFO_0004985, GO_1903493 | |
| Disease | clopidogrel metabolite measurement | 3.02e-04 | 33 | 23 | 2 | EFO_0007966 | |
| Disease | response to anticoagulant | 4.68e-04 | 41 | 23 | 2 | GO_0061476 | |
| Disease | Kidney Failure, Chronic | 6.41e-04 | 48 | 23 | 2 | C0022661 | |
| Disease | hair morphology measurement | 8.11e-04 | 54 | 23 | 2 | EFO_0007821 | |
| Disease | ecosanoids measurement | 8.42e-04 | 55 | 23 | 2 | EFO_0020044 | |
| Disease | chronic obstructive pulmonary disease | 1.82e-03 | 688 | 23 | 4 | EFO_0000341 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| ERLEQRQACEDELRE | 61 | O75150 | |
| LRQCRVIDEQDEEEV | 51 | Q9BWT7 | |
| LAEEVQRLRARCEEE | 171 | Q16352 | |
| HLQEEQRRREEEEDE | 896 | P78312 | |
| ADDEIEETRVNCRRE | 256 | Q9H0G5 | |
| EQLRELSREREEEDD | 286 | Q99795 | |
| DERLRCAELEREVAE | 261 | Q96ED9 | |
| LCREQLLEREEEIAE | 91 | O75145 | |
| ERRDQELRRLEEEAC | 921 | Q9HD67 | |
| ELNVCREQLLEREEE | 96 | Q13136 | |
| QEERLREQEERLCEQ | 211 | A6NEY3 | |
| REQEERLCEQEERLR | 216 | A6NEY3 | |
| RLCEQEERLREQEER | 221 | A6NEY3 | |
| EQEERLREQEERLCE | 231 | A6NEY3 | |
| LREQEERLCEQEERL | 236 | A6NEY3 | |
| ERLCEQEERLREHEE | 241 | A6NEY3 | |
| QEERLREHEERLCEQ | 246 | A6NEY3 | |
| EERLCEQEERLREQE | 261 | A6NEY3 | |
| ERLHEQEERLCEQEE | 276 | A6NEY3 | |
| QEERLCEQEERLREQ | 281 | A6NEY3 | |
| RLREQEERLCEQEER | 291 | A6NEY3 | |
| EERLCEQEERLREQE | 296 | A6NEY3 | |
| EQEERLREQEERLCE | 301 | A6NEY3 | |
| LREQEERLCEQEERL | 306 | A6NEY3 | |
| ERLCEQEERLREQEE | 311 | A6NEY3 | |
| QEERLREQEERLCEQ | 316 | A6NEY3 | |
| EERLREQEERLCEQE | 226 | A6NEF3 | |
| EQEERLCEQEERLRE | 231 | A6NEF3 | |
| ERLREHEERLCEQEE | 241 | A6NEF3 | |
| RLCEQEERLREQEER | 256 | A6NEF3 | |
| ERLREQEERLCEQEE | 276 | A6NEF3 | |
| QEERLCEQEERLREQ | 281 | A6NEF3 | |
| RLREQEERLCEQEER | 291 | A6NEF3 | |
| EERLCEQEERLREQE | 296 | A6NEF3 | |
| EQEERLREQEERLCE | 301 | A6NEF3 | |
| ERLREQEERLCEQEE | 206 | A6NEM1 | |
| RLCEQEERLREQEER | 221 | A6NEM1 | |
| EERLREQEERLCEQE | 226 | A6NEM1 | |
| HEQEERLCEQEERLR | 216 | A6NI86 | |
| RLCEQEERLREQEER | 221 | A6NI86 | |
| EERLREQEERLCEQE | 226 | A6NI86 | |
| EQEERLCEQEERLRE | 231 | A6NI86 | |
| LCEQEERLREQEERL | 236 | A6NI86 | |
| ERLREQEERLCEQEE | 241 | A6NI86 | |
| QEERLCEQEERLREQ | 246 | A6NI86 | |
| RLREQEERLCEQEER | 256 | A6NI86 | |
| EERLCEQEERLREQE | 261 | A6NI86 | |
| ERLREQEERLCEQEE | 276 | A6NI86 | |
| RLCEQEERLREQEER | 291 | A6NI86 | |
| EERLREQEERLCEQE | 296 | A6NI86 | |
| HEQEERLCEQEERLR | 216 | H0YKK7 | |
| RLCEQEERLREQEER | 221 | H0YKK7 | |
| EERLREQEERLCEQE | 226 | H0YKK7 | |
| EQEERLCEQEERLRE | 231 | H0YKK7 | |
| LCEQEERLREQEERL | 236 | H0YKK7 | |
| ERLREQEERLCEQEE | 241 | H0YKK7 | |
| QEERLCEQEERLREQ | 246 | H0YKK7 | |
| RLREQEERLCEQEER | 256 | H0YKK7 | |
| EERLCEQEERLREQE | 261 | H0YKK7 | |
| EQEERLREQEERLCE | 266 | H0YKK7 | |
| LREQEERLCEQEERL | 271 | H0YKK7 | |
| ERLCEQEERLREQEE | 276 | H0YKK7 | |
| QEERLREQEERLCEQ | 281 | H0YKK7 | |
| REQEERLCEQEERLR | 286 | H0YKK7 | |
| RLCEQEERLREQEER | 291 | H0YKK7 | |
| EERLREQEERLCEQE | 296 | H0YKK7 | |
| EQEERLCEQEERLRE | 301 | H0YKK7 | |
| LCEQEERLREQEERL | 306 | H0YKK7 | |
| ERLREQEERLCEQEE | 311 | H0YKK7 | |
| EARVEEEEERCQHLQ | 921 | P35579 | |
| LEQEVRRLREECLQE | 546 | Q8WYA0 | |
| IEDRVQEEARCLVEE | 141 | P33261 | |
| LDELLVRLEEEQQRC | 96 | Q9BV73 | |
| REQREKEEEERQREE | 611 | Q8IWC1 | |
| IEDRVQEEARCLVEE | 141 | P33260 | |
| IEDRVQEEARCLVEE | 141 | P11712 | |
| REELCRQIQEEEDEK | 26 | O43805 | |
| DAELRERLRQCEETI | 46 | Q6NZY4 | |
| ELCLQREQREELERL | 176 | A6NEE1 | |
| REDQEEELEDVRQSC | 1736 | Q8IUG5 | |
| RERQCREEEELQQEE | 1106 | Q07283 |